Strides Pharma Science Ltd

Strides Pharma Science Reports FY2026 Results: Revenue Up 6.4% to ₹48,586.83M 📈

- Consolidated revenue for FY2026: ₹48,586.83M vs ₹45,653.35M (previous year).

- Profit before tax: ₹6,686.86M vs ₹4,869.21M (previous year).

- Profit after tax (continuing operations): ₹5,745.20M vs ₹4,094.05M (previous year).

- Basic EPS (continuing operations): ₹60.34 vs ₹44.05 (previous year).

- Total comprehensive income: ₹6,185.43M (FY2026) vs ₹37,473.24M (FY2025, included discontinued ops gain).

- Total assets as of March 31, 2026: ₹69,272.32M vs ₹60,487.25M (previous year).

- Final dividend recommended: ₹5 per equity share (50%).